https://www.selleckchem.com/pr....oducts/heparan-sulfa
65 [0.54, 0.78], p 0.00001), or from the time of primary diagnosis (PD survival HR 0.74 [0.57-0.95], p = 0.02). Dual therapy was also associated with improved local control, indicating an additive effect of the two treatments (HR 0.53 [0.31-0.93], p=0.03). Intracranial hemorrhage was higher in patients receiving BRAF inhibitors plus SRS than in those receiving SRS alone (OR, 3.16 [1.43-6.96], p = 0.004). BRAF inhibitors in conjunction with SRS as local treatment appear to be efficacious. Local brain control and survival imp
Like
Comment
Share
